Fundraising FoxAkribion Therapeutics
1 known investors
Find your way into Akribion Therapeutics
Sign up to see every warm intro you have to Akribion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Akribion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Akribion Therapeutics develops an RNA-guided, nuclease enzyme-based technology for programmable cell depletion using its G-dase E payload. The company initially targets HPV-induced oropharyngeal head and neck cancer (OPSCC) and is exploring further applications in precision oncology.
Investors · 1
Frequently asked questions
- What does Akribion Therapeutics do?
- Akribion Therapeutics develops an RNA-guided, nuclease enzyme-based technology for programmable cell depletion using its G-dase E payload. The company initially targets HPV-induced oropharyngeal head and neck cancer (OPSCC) and is exploring further applications in precision oncology.
- Who are Akribion Therapeutics's investors?
- Akribion Therapeutics's investors include RV Invest GmbH.